Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr;270(4):1945-1954.
doi: 10.1007/s00415-022-11509-w. Epub 2022 Dec 23.

Salivary Aβ1-42 may be a quick-tested biomarker for clinical use in Alzheimer's disease: a meta-analysis

Ziqi Fan #  1 , Zheyu Li #  2 , Shuai Zhao  2 , Yanxing Chen  2 , Yujie Su  1 , Guoping Peng  1 , Benyan Luo  3
Affiliations
Review

Salivary Aβ1-42 may be a quick-tested biomarker for clinical use in Alzheimer's disease: a meta-analysis

Ziqi Fan et al. J Neurol. 2023 Apr.

Abstract

Objective: Alzheimer's disease (AD) is the most prevalent form of dementia among the aging population. Cumulative studies aim to find non-invasive biomarkers in the early stages of AD. Saliva can be obtained easily, and salivary biomarkers have been proven effective in detecting neurodegenerative diseases. To find effective biomarkers in saliva and to help the diagnosis of AD, we performed a meta-analysis focusing on the salivary biomarkers (β-amyloid 1-42 (Aβ1-42), total tau (t-tau), phosphorylated tau (p-tau) and acetylcholinesterase (AChE)) in AD.

Methods: We conducted a systematic online search for eligible studies reporting data on salivary biomarkers reflecting Aβ1-42, t-tau, p-tau, and AChE in AD cohorts versus controls. Biomarkers' performance was assessed in a random-effects meta-analysis with the ratio of mean (RoM).

Results: A total of thirteen studies were included in the meta-analysis, of them seven involved salivary Aβ1-42 (271 AD and 489 controls), five involved salivary t-tau (324 AD and 252 controls), four involved salivary p-tau (130 AD and 161 controls), and three involved salivary AChE (81 AD and 54 controls). AD showed significantly higher salivary Aβ1-42 levels than control (ROM = 1.90 (95% CI 1.28-2.81, P = 0.001), while AD and control did not differ significantly on salivary t-tau, p-tau and AChE (ROM = 0.94, 95% CI 0.67-1.31, P = 0.72; ROM = 0.91, 95% CI 0.56-1.45, P = 0.68; ROM = 0.83, 95% CI 0.24-2.88, P = 0.77; respectively).

Conclusion: The pooled results provide evidence that salivary Aβ1-42 may serve as a sensitive biomarker for AD; nevertheless, larger AD cohorts are required to further confirm the sensitivity and specificity of salivary Aβ1-42 for AD diagnosis.

Keywords: Acetylcholinesterase; Alzheimer’s disease; Phosphorylated tau; Salivary biomarkers; Total tau; β-amyloid 1–42.

PubMed Disclaimer

Comment in

References

    1. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121(2):171–181. https://doi.org/10.1007/s00401-010-0789-4 - DOI - PubMed
    1. Selkoe DJ (2001) Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3(1):75–80. https://doi.org/10.3233/jad-2001-3111 - DOI - PubMed
    1. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562. https://doi.org/10.1016/j.jalz.2018.02.018 - DOI - PubMed - PMC
    1. Blennow K, Zetterberg H (2015) Understanding biomarkers of neurodegeneration: ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med 21(3):217–219. https://doi.org/10.1038/nm.3810 - DOI - PubMed
    1. O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S et al (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement 11(5):549–560. https://doi.org/10.1016/j.jalz.2014.08.099 - DOI - PubMed